Table 1 The clinical characteristics, medication and laboratory indexes of patients

Clinical characteristics

Male, n (%)

62(51.2)

48(48.0)

0.632

Age ≥ 60 years, n (%)

47(38.8)

20(20.0)

0.002*

Bleeding, n (%)

30(24.8)

6(6.0)

<0.001*

Solid malignancies, n (%)

48(39.7)

37(37.0)

0.685

Chronic hepatopathy, n (%)

35(28.9)

28(28.0)

0.879

Infection, n (%)

60(49.6)

27(27.0)

0.001*

COVID-19, n (%)

28(23.1)

6(6.0)

<0.001*

CAR-T therapy, n (%)

47(38.8)

23(23.0)

0.012*

Cumulative dose mg, (IQR)

400(240 ~ 680)

400(160 ~ 700)

0.929

Blood transfusion, n (%)

41(33.9)

19(19.0)

0.013*

Drug combinations, n (%)

Anticoagulants

76(62.8)

42(42.0)

0.002*

Antiplatelet drugs

13(10.7)

13(13.0)

0.604

Antirheumatic drugs

28(23.1)

44(44.0)

0.001*

Glucocorticoids

112(92.6)

82(82.0)

0.017*

Cytotoxic chemotherapeutics

50(41.3)

29(29.0)

0.057

Other drugs associated with HFIB

21(17.4)

5(5.0)

0.005*

Laboratory indexes

Baseline fibrinogen g/L, (IQR)

4.05(2.97 ~ 5.19)

4.60(3.32 ~ 5.67)

0.051

CRP mg/dL, (IQR)

4.74(0.89 ~ 10.06)

3.69(0.71 ~ 7.51)

0.419

ALT U/L, (IQR)

19.20(11.65 ~ 39.55)

17.20(11.08 ~ 30.00)

0.274

AST U/L, (IQR)

21.90(14.30 ~ 41.40)

18.25(13.00 ~ 32.65)

0.140

ALB g/L, (x ± s)

34.26 ± 5.73

35.25 ± 5.18

0.182

TBIL μmol/L, (IQR)

9.10(6.70 ~ 14.40)

8.05(4.98 ~ 12.70)

0.019*

TT s, (IQR)

15.90(14.75 ~ 16.95)

15.80(15.03 ~ 16.98)

0.512

PT s, (IQR)

13.90(13.00 ~ 15.00)

13.45(12.50 ~ 14.40)

0.011*

INR (IQR)

1.08(1.00 ~ 1.20)

1.03(0.95 ~ 1.13)

0.007*

D-Dimer μg/mL, (IQR)

2.04(0.62 ~ 5.39)

1.49(0.64 ~ 3.59)

0.156